newsfilter
← Latest News
PR Newswire·

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced PIONEER trial results highlighting the long-term efficacy and safety of AYVAKIT®...